Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07848243 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
\[18F\]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and/or recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumors
Trial Details
NCT Number NCT07848243
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions
(from sponsor)		 Lung Cancer (NSCLC), Cervical Squamous Cell Cancer, Melanoma (Skin Cancer), Breast Cancer, Gastrointestinal Cancers
Related terms Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Melanoma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov